Phaseline

Targets › PNP

PNP (Purine nucleoside phosphorylase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2028.

Catalyzes the phosphorolytic breakdown of the N-glycosidic bond in the beta-(deoxy)ribonucleoside molecules, with the formation of the corresponding free purine bases and pentose-1-phosphate. Preferentially acts on 6-oxopurine nucleosides including inosine and guanosine. (UniProt, P00491)

Open in Phaseline: the race on PNP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Roswell Park Cancer InstituteTrifluridine and Tipiracil Hydrochloride
Nucleoside analog (thymidine derivative) and thymidine phosphorylase inhibitor; inhibits D
TYMS, PNPPhase 1Advanced Malignant Solid NeoplasmSep 2028

Conditions

Advanced Malignant Solid Neoplasm (1)

Modalities

small molecule (1)

Companies

Roswell Park Cancer Institute (1)

Related targets

TYMS (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.